143 related articles for article (PubMed ID: 32185869)
1. Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies.
Ladwig JE; Zhu X; Rolandi P; Hart R; Robinson J; Rydholm A
Biotechnol Prog; 2020 Sep; 36(5):e2993. PubMed ID: 32185869
[TBL] [Abstract][Full Text] [Related]
2. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
[TBL] [Abstract][Full Text] [Related]
3. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
[TBL] [Abstract][Full Text] [Related]
5. Designing scalable ultrafiltration/diafiltration process of monoclonal antibodies via mathematical modeling by coupling mass balances and Poisson-Boltzmann equation.
Ambrožič R; Arzenšek D; Podgornik A
Biotechnol Bioeng; 2021 Feb; 118(2):633-646. PubMed ID: 33049074
[TBL] [Abstract][Full Text] [Related]
6. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
Teeters M; Bezila D; Benner T; Alfonso P; Alred P
Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
[TBL] [Abstract][Full Text] [Related]
7. Predicting Formulation Conditions During Ultrafiltration and Dilution to Drug Substance Using a Donnan Model with Homology-Model Based Protein Charge.
Kannan A; Chinn M; Izadi S; Maier A; Dvornicky J; Fedesco M; Day E; Ladiwala A; Woys A
J Pharm Sci; 2023 Mar; 112(3):820-829. PubMed ID: 36336103
[TBL] [Abstract][Full Text] [Related]
8. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
Thakur G; Hebbi V; Rathore AS
Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
[TBL] [Abstract][Full Text] [Related]
9. Mass Balance Model with Donnan Equilibrium Accurately Describes Unusual pH and Excipient Profiles during Diafiltration of Monoclonal Antibodies.
Baek Y; Singh N; Arunkumar A; Borwankar A; Zydney AL
Biotechnol J; 2019 Jul; 14(7):e1800517. PubMed ID: 30791230
[TBL] [Abstract][Full Text] [Related]
10. Developability Assessments of Monoclonal Antibody Candidates to Minimize Aggregation During Large-Scale Ultrafiltration and Diafiltration (UF-DF) Processing.
Whitaker N; Pace SE; Merritt K; Tadros M; Khossravi M; Deshmukh S; Cheng Y; Joshi SB; Volkin DB; Dhar P
J Pharm Sci; 2022 Nov; 111(11):2998-3008. PubMed ID: 35940242
[TBL] [Abstract][Full Text] [Related]
11. Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.
Holstein M; Hung J; Feroz H; Ranjan S; Du C; Ghose S; Li ZJ
Biotechnol Bioeng; 2020 Nov; 117(11):3591-3606. PubMed ID: 32687221
[TBL] [Abstract][Full Text] [Related]
12. pH and excipient profiles during formulation of highly concentrated biotherapeutics using bufferless media.
Jabra MG; Tao Y; Moomaw JF; Yu Z; Hotovec BJ; Geng SB; Zydney AL
Biotechnol Bioeng; 2020 Nov; 117(11):3390-3399. PubMed ID: 32667708
[TBL] [Abstract][Full Text] [Related]
13. Preparation of milk protein concentrates by ultrafiltration and continuous diafiltration: Effect of process design on overall efficiency.
Gavazzi-April C; Benoit S; Doyen A; Britten M; Pouliot Y
J Dairy Sci; 2018 Nov; 101(11):9670-9679. PubMed ID: 30172402
[TBL] [Abstract][Full Text] [Related]
14. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
Yang Y; Velayudhan A; Thornhill NF; Farid SS
Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
[TBL] [Abstract][Full Text] [Related]
15. Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration.
West JM; Feroz H; Xu X; Puri N; Holstein M; Ghose S; Ding J; Li ZJ
Biotechnol Bioeng; 2021 Jun; 118(6):2293-2300. PubMed ID: 33666234
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of ultrafiltration/diafiltration in removing organic and elemental process equipment related leachables from biological therapeutics.
Sun B; Hadidi M; Santiago Nuñez J; Song B; Tumambac GE; Wong K; Kalinowski G; Hathcock JJ
Biotechnol Prog; 2024; 40(1):e3400. PubMed ID: 37964726
[TBL] [Abstract][Full Text] [Related]
17. Streamlining process characterization efforts using the high throughput ambr® crossflow system for ultrafiltration and diafiltration processing of monoclonal antibodies.
Fernandez-Cerezo L; Benner SW; Pollard JM
Biotechnol Prog; 2021 May; 37(3):e3118. PubMed ID: 33369289
[TBL] [Abstract][Full Text] [Related]
18. Multi-attribute PAT for UF/DF of Proteins-Monitoring Concentration, particle sizes, and Buffer Exchange.
Rolinger L; Rüdt M; Diehm J; Chow-Hubbertz J; Heitmann M; Schleper S; Hubbuch J
Anal Bioanal Chem; 2020 Apr; 412(9):2123-2136. PubMed ID: 32072210
[TBL] [Abstract][Full Text] [Related]
19. Effects of Impurities from Sugar Excipient on Filtrate Flux during Ultrafiltration and Diafiltration Process.
Lee J; Na J; Baek Y
Membranes (Basel); 2021 Oct; 11(10):. PubMed ID: 34677543
[TBL] [Abstract][Full Text] [Related]
20. Introduction and clearance of beta-glucan in the downstream processing of monoclonal antibodies.
Kluters S; Steinhauser K; Pfänder R; Studts J
Biotechnol Prog; 2021 Jul; 37(4):e3149. PubMed ID: 33743183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
